Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
Sign Up to like & getrecommendations! Published in 2017 at "Haematologica"
DOI: 10.3324/haematol.2017.171041
Abstract: The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib patients. We pooled data from 1505 chronic lymphocytic leukemia and… read more here.
Keywords: atrial fibrillation; randomized controlled; characterization atrial; fibrillation adverse ... See more keywords